Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958 · TroFuse-005 Phase 3Active, not recruiting
- Lead sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 710 (estimated)
- Start date
- 6 Dec 2023
- Primary completion
- 10 Jan 2028 (estimated)
- Study completion
- 10 Jan 2028
- Last update posted
- 28 Aug 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Sacituzumab tirumotecan Biological
- Doxorubicin Drug
- Paclitaxel Drug
- Nab-paclitaxel Drug
- Rescue medications Drug
Conditions and primary outcome
- Endometrial Cancer
Primary outcome
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 27 months); Overall Survival (OS) (Up to approximately 48 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06132958.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06132958 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.